Takeda's Dengue vaccine candidate shows efficacy in children aged 4 to 16, regardless of previous exposure to dengue fever online

                       Save up to 90%! Free deposit check (**********************************************************************) 80 6400                   Fri (*********************************************************************. 11. 2019 – 08: 43               DAX 13. 245, 00 – 0, 33% Dow Jones27.634, 00 -0, 17% EUR / USD1, 1022 – 0, 25% Gold1. 462 13 – 0, 45% TecDAX2 . 925 76 – 0, 08% US Tech 1008. 236 50 + 0 20% Bitcoin8. 775, 25 -4, 50% Oil (Brent) 62, 38 +0, 20%                                                                                                                                               News source: Business Wire         | (08. . 2019, 00: 25 |                              195             |                                     0                 |                                                                                                     Takeda Pharmaceutical Company Limited (TSE: 4502 / NYSE: TAK) (“Takeda”) announced today that results from the primary endpoint analysis of the ongoing pivotal Phase 3 Trial Tetravalent Immunization Against Dengue Efficacy Study (TIDES ) on its Dengue vaccine candidate (TAK – (***************************************************************************************************)) in the New England Journal of Medicine   were published. Takeda’s dengue vaccine candidate provided protection against virologically confirmed dengue fever (VCD), which was the primary endpoint of the study in children aged   four to 00 years ago. Vaccine Efficacy (VE) was at 80 2% 95% Confidence interval [KI]: 73, 3% to 85, 3%; p
Read More

LEAVE A REPLY

Please enter your comment!
Please enter your name here